Japan· JP-1179040F4020
ミルナシプラン塩酸塩
A milnacipran product containing ミルナシプラン塩酸塩, registered in Japan by 旭化成セラピューティクス, on the national reimbursement list. The same ATC class is registered in 6 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Milnacipran is registered in 6 of 19 countries.
Countries holding a registration under ATC N06AX17 (milnacipran), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 3 of them publish a price we can compare per daily dose
Milnacipran · ATC N06AX17
6 / 19 countries
- Finlandprice
- Franceprice
- Germany
- Japan
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of milnacipran costs, country by country.
Normalised to the WHO defined daily dose (0.1 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Milnacipran · price per daily dose (0.1 g)
USD · FX 28 Sept 2026
- US United States$24.47 (acquisition cost)
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- ミルナシプラン塩酸塩
- Manufacturer
- 旭化成セラピューティクス
- Country
- Japan (JP)
- ATC code
- N06AX17
- ATC class
- Milnacipran
- Defined daily dose
- 0.1 g, O
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
194 interactions on record for milnacipran.
Graded by severity as the source publishes them — 27 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Milnacipran · interactions on record
194 records
- 27 severe
- 167 moderate
Most severe, free to view
- OndansetronA04AA01severe
- GranisetronA04AA02severe
- DolasetronA04AA04severe
- PalonosetronA04AA05severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under N06AX17
Milnacipran, as other registers publish it.
- FinlandIxelParanova Oy
- FinlandIxelOrifarm Oy
- FinlandIxelPierre Fabre Pharma Norden AB
- FinlandIxelPierre Fabre Pharma Norden AB
- United KingdomMilnacipran 50mg capsulesSpecial Order
- FranceMILNACIPRAN ARROW 25 mg, géluleARROW GENERIQUES
- FranceMILNACIPRAN ARROW 50 mg, géluleARROW GENERIQUES
- FranceMILNACIPRAN EG 25 mg, géluleDOUBLE-E PHARMA (IRLANDE)
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/afc5642f-085a-4f1d-ba1e-10bee3d1b62b GET /v1/drugs/afc5642f-085a-4f1d-ba1e-10bee3d1b62b?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "５０ｍｇ１錠",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "1179040F4020",
"category": "内用薬",
"price_yen": 17.3,
"generic_name": "ミルナシプラン塩酸塩",
"product_name_jp": null,
"therapeutic_class": "1179",
"transitional_expiry": null
}See everything about milnacipran.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.